R&G PharmaStudies Co. Ltd. A (301333) — Tangible Net Worth Ratio
R&G PharmaStudies Co. Ltd. A (301333) has a Tangible Net Worth Ratio of 99.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥15.35 Million) from net assets (CN¥2.00 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See R&G PharmaStudies Co. Ltd. A short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
R&G PharmaStudies Co. Ltd. A Tangible Net Worth Ratio (2019–2025)
This chart shows how R&G PharmaStudies Co. Ltd. A's Tangible Net Worth Ratio has changed across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 99.2%, reflecting net assets of CN¥2.00 Billion with intangible assets of CN¥15.35 Million CNY. See 301333 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for R&G PharmaStudies Co. Ltd. A from 2019 to 2025, covering 7 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 301333 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 99.2% | CN¥1.98 Billion | CN¥16.25 Million | CN¥2.40 Billion | ▲ +0.2 pp |
| 2024 | 98.9% | CN¥1.84 Billion | CN¥19.43 Million | CN¥2.34 Billion | ▼ 0.0 pp |
| 2023 | 99.0% | CN¥1.75 Billion | CN¥17.93 Million | CN¥2.07 Billion | ▼ -0.2 pp |
| 2022 | 99.2% | CN¥1.59 Billion | CN¥12.83 Million | CN¥1.88 Billion | ▲ +3.3 pp |
| 2021 | 95.9% | CN¥437.81 Million | CN¥17.88 Million | CN¥677.47 Million | ▲ +2.7 pp |
| 2020 | 93.2% | CN¥336.98 Million | CN¥22.96 Million | CN¥536.36 Million | ▲ +0.5 pp |
| 2019 | 92.7% | CN¥249.74 Million | CN¥18.16 Million | CN¥446.86 Million | — |